A recent study has highlighted the role of phosphoglycerate kinase 1 (PGK1) in promoting tumorigenesis and sorafenib resistance in ccRCC by activating the CXCR4/ERK pathway and enhancing glycolysis [28]. Here, CXCR4 is linked to nonpapillary renal cell carcinoma.